624 related articles for article (PubMed ID: 24983194)
1. [New treatment options for metastatic melanoma].
Tietze JK; Berking C
Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
[No Abstract] [Full Text] [Related]
2. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
3. The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.
Akabane H; Sullivan RJ
Am J Clin Dermatol; 2016 Feb; 17(1):1-10. PubMed ID: 26518880
[TBL] [Abstract][Full Text] [Related]
4. The future of melanoma therapy: developing new drugs and improving the use of old ones.
Palumbo G; Di Lorenzo G; Ottaviano M; Damiano V
Future Oncol; 2016 Nov; 12(22):2531-2534. PubMed ID: 27715206
[No Abstract] [Full Text] [Related]
5. Strides in melanoma announced: maximizing value comes next.
Tuma RS
J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727
[No Abstract] [Full Text] [Related]
6. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
Jarkowski A; Norris L; Trinh VA
Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
[TBL] [Abstract][Full Text] [Related]
7. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
9. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
Van Allen EM; Wagle N; Sucker A; Treacy DJ; Johannessen CM; Goetz EM; Place CS; Taylor-Weiner A; Whittaker S; Kryukov GV; Hodis E; Rosenberg M; McKenna A; Cibulskis K; Farlow D; Zimmer L; Hillen U; Gutzmer R; Goldinger SM; Ugurel S; Gogas HJ; Egberts F; Berking C; Trefzer U; Loquai C; Weide B; Hassel JC; Gabriel SB; Carter SL; Getz G; Garraway LA; Schadendorf D;
Cancer Discov; 2014 Jan; 4(1):94-109. PubMed ID: 24265153
[TBL] [Abstract][Full Text] [Related]
10. [Targeted molecular therapies (except immunotherapy)].
Roux J; Pages C; Lebbé C
Bull Cancer; 2014 Dec; 101 Suppl 2():S25-36. PubMed ID: 25776764
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Lim SY; Menzies AM; Rizos H
Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
[TBL] [Abstract][Full Text] [Related]
12. [Translational research and diagnostics of melanoma].
Rüschoff J; Kleinschmidt M; Middel P
Pathologe; 2012 Nov; 33 Suppl 2():291-5. PubMed ID: 22968732
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
14. Overcoming metastatic melanoma with BRAF inhibitors.
Hong S; Hong S; Han SB
Arch Pharm Res; 2011 May; 34(5):699-701. PubMed ID: 21656352
[TBL] [Abstract][Full Text] [Related]
15. Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive.
Gabeff R; Dutartre H; Khammari A; Boisrobert A; Nguyen JM; Quereux G; Brocard A; Saint-Jean M; Peuvrel L; Dreno B
Eur J Dermatol; 2015; 25(5):452-6. PubMed ID: 26242321
[TBL] [Abstract][Full Text] [Related]
16. Interaction of molecular alterations with immune response in melanoma.
Szczepaniak Sloane RA; Gopalakrishnan V; Reddy SM; Zhang X; Reuben A; Wargo JA
Cancer; 2017 Jun; 123(S11):2130-2142. PubMed ID: 28543700
[TBL] [Abstract][Full Text] [Related]
17. [New hope in metastatic melanoma treatment?].
Guillot B
Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
[No Abstract] [Full Text] [Related]
18. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
Sibaud V; Lamant L; Maisongrosse V; Delord JP
Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
[TBL] [Abstract][Full Text] [Related]
19. Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy.
Satzger I; Degen A; Asper H; Kapp A; Hauschild A; Gutzmer R
J Clin Oncol; 2013 May; 31(13):e220-2. PubMed ID: 23530102
[No Abstract] [Full Text] [Related]
20. The new paradigm of systemic therapies for metastatic melanoma.
Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
